title: [Evaluation of the postnatal treatment efficacy in congenital toxoplasmosis identified by the newborn screening programme].
abstract: The effectiveness of neonatal screening for anti-Toxoplasma IgM or IgA and IgM specific antibodies followed by an intensive anti-parasitic therapy for a prevention of clinical and immunological reactivations of congenital infection was studied. Thirty-five congenitally infected infants were included into clinical and serological follow-up. The children were mostly asymptomatic at birth or they expressed some non-specific reversible clinical abnormalities in neonatal period. Clinically overt toxoplasmosis occurred in 10 patients, including one infant with a severe form; 2 children had co-existing CMV infections. During the follow-up period, no clinical relapses were reported. Asymptomatic immunological rebounds of IgG or of IgG and IgA specific antibodies were observed in 16 patients. Anti-parasitic treatment initiated soon after birth seems to be promising in a prevention of early clinical sequelae of congenital T. gondii infection.
authors.affiliation: Klinika Chorób Pasozytniczych i Tropikalnych AM, 60-355 Poznań, ul. Przybyszewskiego 49.
authors.forename: M
authors.initials: M
authors.lastname: Paul
authors.forename: A
authors.initials: A
authors.lastname: Jaworska
authors.forename: H
authors.initials: H
authors.lastname: Twardosz-Pawlik
authors.forename: J
authors.initials: J
authors.lastname: Szczapa
authors.forename: J
authors.initials: J
authors.lastname: Stefaniak
mesh_terms: D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D002493:Central Nervous System Diseases / Q000175:diagnosis* / Q000517:prevention & control; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood*; D007223:Infant; D007231:Infant, Newborn; D015997:Neonatal Screening / Q000458:organization & administration*; D011044:Poland / Q000453:epidemiology; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000175:diagnosis* / Q000517:prevention & control*; D015397:Program Evaluation; D014122:Toxoplasma; D014125:Toxoplasmosis, Congenital / Q000175:diagnosis* / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000913:Antibodies, Protozoan; D007075:Immunoglobulin M